Passenger deletions generate therapeutic vulnerabilities in cancer

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works

Integrative Genomic Profiling of Human Prostate Cancer

Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,653 · see citing works

The Genetic Landscape of a Cell

Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162 · see citing works

Glutamine addiction: a new therapeutic target in cancer

Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770 · see citing works

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683 · see citing works

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · see citing works

Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans

Sönnichsen, B., Koski, L. B., Walsh, A., Marschall, P., Neumann, B., Brehm, M., Alleaume, A.-M., Artelt, J., Bettencourt, P. J. G., Cassin, E., et al. (2005) · Nature · doi:10.1038/nature03353 · Cited by 886 · see citing works

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767 · see citing works

Signatures of mutation and selection in the cancer genome

Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08768 · Cited by 707 · see citing works

Translation of the Philadelphia chromosome into therapy for CML

Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 665 · see citing works

Innate versus learned odour processing in the mouse olfactory bulb

Kobayakawa, K., Kobayakawa, R., Matsumoto, H., Oka, Y., Imai, T., Ikawa, M., Okabe, M., Ikeda, T., Itohara, S., Kikusui, T., et al. (2007) · Nature · doi:10.1038/nature06281 · Cited by 659 · see citing works

The Carnegie Protein Trap Library: A Versatile Tool for Drosophila Developmental Studies

Buszczak, M., Paterno, S., Lighthouse, D. V., Bachman, J. L., Planck, J. L., Owen, S., Skora, A. D., Nystul, T. G., Ohlstein, B., Allen, A. K., et al. (2006) · Genetics · doi:10.1534/genetics.106.065961 · Cited by 578 · see citing works

High-resolution genomic profiles of human lung cancer

Tonon, G., Wong, K., Maulik, G., Brennan, C. W., Feng, B., Zhang, Y., Khatry, D., Protopopov, A. I., You, M. J., Aguirre, A. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504126102 · Cited by 398 · see citing works

The Quest for the 1p36 Tumor Suppressor

Bagchi, A., & Mills, A. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2095 · Cited by 196 · see citing works

Multiple knockout analysis of genetic robustness in the yeast metabolic network

Deutscher, D., Meilijson, I., Kupiec, M., & Ruppin, E. (2006) · Nature Genetics · doi:10.1038/ng1856 · Cited by 195 · see citing works

Exposing the fitness contribution of duplicated genes

DeLuna, A., Vetsigian, K., Noam Shoresh, F., Hegreness, M., Colón‐González, M., Chao, S., & Kishony, R. (2008) · Nature Genetics · doi:10.1038/ng.123 · Cited by 177 · see citing works

β‐enolase deficiency, a new metabolic myopathy of distal glycolysis

Comi, G. P., Fortunato, F., Lucchiari, S., Bordoni, A., Prelle, A. C., Jann, S., Keller, A., Ciscato, P., Galbiati, S., Chiveri, L. R., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1095 · Cited by 131 · see citing works

High-resolution Global Genomic Survey of 178 Gliomas Reveals Novel Regions of Copy Number Alteration and Allelic Imbalances

Kotliarov, Y., Steed, M. E., Christopher, N., Walling, J., Su, Q., Heiss, J. D., Rosenblum, M., Mikkelsen, T., Zenklusen, J. C., & Fine, H. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1691 · Cited by 127 · see citing works

Downregulation of RUNX3 and TES by hypermethylation in glioblastoma

Mueller, W. C., Nutt, C. L., Ehrich, M., Riemenschneider, M. J., von Deimling, A., van den Boom, D., & Louis, D. N. (2006) · Oncogene · doi:10.1038/sj.onc.1209805 · Cited by 119 · see citing works

Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes

Duncan, C. G., Killela, P. J., Payne, C. A., Lampson, B. L., Chen, W., Liu, J., Solomon, D. A., Waldman, T. A., Towers, A. J., Gregory, S. G., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.137 · Cited by 114 · see citing works

PARP inhibitors stumble in breast cancer

Guha, M. (2011) · Nature Biotechnology · doi:10.1038/nbt0511-373 · Cited by 112 · see citing works

Widespread conservation of genetic redundancy during a billion years of eukaryotic evolution

Vavouri, T., Semple, J. I., & Lehner, B. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.08.005 · Cited by 108 · see citing works

A survey of homozygous deletions in human cancer genomes

Cox, C., Bignell, G. R., Greenman, C., Stabenau, A., Warren, W., Stephens, P., Davies, H. R., Watt, S. B., Teague, J. W., Edkins, S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408593102 · Cited by 101 · see citing works

High-Resolution Genomic Copy Number Profiling of Glioblastoma Multiforme by Single Nucleotide Polymorphism DNA Microarray

Yin, D., Ogawa, S., Kawamata, N., Tunici, P., Finocchiaro, G., Eoli, M., Rückert, C., Huynh, T. P., Liu, G., Kato, M., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0270 · Cited by 101 · see citing works

CAMTA1 , a 1p36 Tumor Suppressor Candidate, Inhibits Growth and Activates Differentiation Programs in Neuroblastoma Cells

Henrich, K., Bauer, T., Schulte, J. H., Ehemann, V., Deubzer, H. E., Gogolin, S., Muth, D., Fischer, M., Benner, A., König, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3014 · Cited by 100 · see citing works

Reaction intermediate analogs for enolase

Anderson, V. E., Weiss, P. M., & Cleland, W. W. (1984) · Biochemistry · doi:10.1021/bi00307a038 · Cited by 84 · see citing works

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

Soto, J. A. D., & Deng, C. (2006) · International Journal of Medical Sciences · doi:10.7150/ijms.3.117 · Cited by 72 · see citing works

Inhibition of purified enolases from oral bacteria by fluoride

Guha‐Chowdhury, N., Clark, A. G., & Sissons, C. H. (1997) · Oral Microbiology and Immunology · doi:10.1111/j.1399-302x.1997.tb00623.x · Cited by 69 · see citing works

Array‐based comparative genomic hybridization analysis of high‐grade neuroendocrine tumors of the lung

Peng, W., Shibata, T., Katoh, H., Kokubu, A., Matsuno, Y., Asamura, H., Tsuchiya, R., Kanai, Y., Hosoda, F., Sakiyama, T., et al. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00092.x · Cited by 55 · see citing works

Genetic Redundancy

Brookfield, J. F. Y. (1997) · Advances in genetics · doi:10.1016/s0065-2660(08)60308-9 · Cited by 47 · see citing works

Structural flexibility in Trypanosoma brucei enolase revealed by X‐ray crystallography and molecular dynamics

Navarro, M. V. A. S., Dias, S. M. G., Mello, L. V., Giotto, M. T. S., Gavalda, S., Blonski, C., Garratt, R. C., & Rigden, D. J. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.06027.x · Cited by 46 · see citing works

Structure of the bis divalent cation complex with phosphonoacetohydroxamate at the active site of enolase

Poyner, R. R., & Reed, G. H. (1992) · Biochemistry · doi:10.1021/bi00146a020 · Cited by 42 · see citing works

Synthetic lethality-based targets for discovery of new cancer therapeutics.

Weidle, U. H., Maisel, D., & Eick, D. (2011) · PubMed · Cited by 40 · see citing works

Role of 5′-AMP-activated protein kinase in stimulation of glucose transport in response to inhibition of oxidative phosphorylation

Jing, M. X., & Ismail‐Beigi, F. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00321.2005 · Cited by 40 · see citing works

Enolase Activity and Isoenzyme Distribution in Human Brain Regions and Tumors

Joseph, J., Cruz-Sánchez, F., & Carreras, J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062484.x · Cited by 34 · see citing works

Chronic Hemolytic Anemia Associated with Erythrocyte Enolase Deficiency Exacerbated by Ingestion of Nitrofurantoin

Stefanini, M. (1972) · American Journal of Clinical Pathology · doi:10.1093/ajcp/58.5.408 · Cited by 31 · see citing works

Critical role of 5′-AMP-activated protein kinase in the stimulation of glucose transport in response to inhibition of oxidative phosphorylation

Jing, M. X., & Ismail‐Beigi, F. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00196.2006 · Cited by 23 · see citing works

Defining a Cancer Dependency Map

Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276 · see citing works

Understanding the Intersections between Metabolism and Cancer Biology

Heiden, M. G. V., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,316 · see citing works

Identification and characterization of essential genes in the human genome

Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015) · Science · doi:10.1126/science.aac7041 · Cited by 1,617 · see citing works

Targeting cancer metabolism in the era of precision oncology

Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189 · see citing works

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0052-4 · Cited by 928 · see citing works

Targeting Metabolism for Cancer Therapy

Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · see citing works

Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening

McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658 · see citing works

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

Mavrakis, K. J., McDonald, E. R., Schlabach, M. R., Billy, E., Hoffman, G. R., deWeck, A., Ruddy, D. A., Venkatesan, K., Yu, J., McAllister, G., et al. (2016) · Science · doi:10.1126/science.aad5944 · Cited by 607 · see citing works

Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects

Isgrò, M. A., Bottoni, P., & Scatena, R. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7215-0_9 · Cited by 577 · see citing works

MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis

Marjon, K., Cameron, M. J., Quang, P., Clasquin, M. F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.043 · Cited by 485 · see citing works

Synthetic lethality as an engine for cancer drug target discovery

Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 470 · see citing works

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501605112 · Cited by 398 · see citing works

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420 · see citing works

Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities

Garofano, L., Migliozzi, S., Oh, Y. T., D’Angelo, F., Najac, R. D., Ko, A., Frangaj, B., Caruso, F. P., Yu, K., Yuan, J., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00159-4 · Cited by 363 · see citing works

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 310 · see citing works

A Synthetic Lethality–Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1

Oike, T., Ogiwara, H., Tominaga, Y., Ito, K., Ando, O., Tsuta, K., Mizukami, T., Shimada, Y., Isomura, H., Komachi, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4593 · Cited by 305 · see citing works

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma

Gopal, R. K., Kübler, K., Calvo, S. E., Polak, P. P., Livitz, D. G., Rosebrock, D., Sadow, P. M., Campbell, B., Donovan, S. E., Amin, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.013 · Cited by 266 · see citing works

Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer

Dey, P., Baddour, J., Muller, F., Wu, C. C., Wang, H., Liao, W.-T., Lan, Z., Chen, A., Gutschner, T., Kang, Y., et al. (2017) · Nature · doi:10.1038/nature21052 · Cited by 264 · see citing works

TP53 loss creates therapeutic vulnerability in colorectal cancer

Liu, Y., Zhang, X., Han, C., Wan, G., Huang, X., Ivan, C., Jiang, D., Rodriguez‐Aguayo, C., Lopez‐Berestein, G., Rao, P. H., et al. (2015) · Nature · doi:10.1038/nature14418 · Cited by 240 · see citing works

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene

Gong, X., Du, J., Parsons, S. H., Merzoug, F. F., Webster, Y., Iversen, P. W., Chio, L.-C., Horn, R. D. V., Lin, X., Blosser, W. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0469 · Cited by 239 · see citing works

Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis

Ohshima, K., & Morii, E. (2021) · Metabolites · doi:10.3390/metabo11010028 · Cited by 230 · see citing works

Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma

Song, Y., Luo, Q., Long, H., Hu, Z. M., Que, T., Zhang, X., Li, Z., Wang, G., Liu, Y., Liu, Z., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-65 · Cited by 221 · see citing works

Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer

Zhao, D., Lü, X., Wang, G., Lan, Z., Liao, W., Li, J., Liang, X., Chen, J., Shah, S. R., Shang, X., et al. (2017) · Nature · doi:10.1038/nature21357 · Cited by 220 · see citing works

An expanded universe of cancer targets

Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.020 · Cited by 213 · see citing works

NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis

Park, M. K., Zhang, L., Min, K., Cho, J.-H., Yeh, C., Moon, H., Hormaechea‐Agulla, D., Mun, H., Ko, S., Lee, J. W., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.11.011 · Cited by 213 · see citing works

Synthetic Lethality in Cancer Therapeutics: The Next Generation

Setton, J. S., Zinda, M. J., Riaz, N., Durocher, D., Zimmermann, M., Koehler, M. T., Reis-Filho, J. S., & Powell, S. N. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1503 · Cited by 211 · see citing works

ENO1 and Cancer

Huang, C. K., Sun, Y., Lv, L., & Ping, Y. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.026 · Cited by 208 · see citing works

ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1

Zhang, T., Sun, L., Hao, Y., Suo, C., Shen, S., Wei, H., Ma, W., Zhang, P., Wang, T., Gu, X., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00299-1 · Cited by 206 · see citing works

Therapeutic targeting of tumor suppressor genes

Morris, L. G. T., & Chan, T. A.-T. (2014) · Cancer · doi:10.1002/cncr.29140 · Cited by 201 · see citing works

Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies

Du, W., & Elemento, O. (2014) · Oncogene · doi:10.1038/onc.2014.291 · Cited by 182 · see citing works

The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation

Molenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., Noorden, C. J. F. V., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 181 · see citing works

Prediction of resistance development against drug combinations by collateral responses to component drugs

Munck, C., Gumpert, H., Wallin, A. I. N., Wang, H. H., & Sommer, M. O. A. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009940 · Cited by 179 · see citing works

The landscape of gene mutations in cirrhosis and hepatocellular carcinoma

Müller, M., Bird, T. G., & Nault, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.019 · Cited by 178 · see citing works

Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer

Kim, H. S., Mendiratta, S., Kim, J., Pecot, C. V., Larsen, J. E., Zubovych, I., Seo, B. Y., Kim, J., Eskiocak, B., Chung, H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.041 · Cited by 172 · see citing works

Glioblastoma Cell–Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance

Li, Z., Meng, X., Wu, P., Zha, C., Han, B., Li, L., Sun, N., Qi, T., Qin, J., Zhang, Y., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0258 · Cited by 168 · see citing works

Impact of cancer metabolism on therapy resistance – Clinical implications

Gonçalves, A. C., Richiardone, E., Jorge, J., Polónia, B. R. G., Xavier, C. P. R., Salaroglio, I. C., Riganti, C., Vasconcelos, M. H., Corbet, C., & Sarmento‐Ribeiro, A. B. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100797 · Cited by 170 · see citing works

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

Marchesini, M., Ogoti, Y., Fiorini, E., Samur, A. A., Nezi, L., D’Anca, M., Storti, P., Samur, M., Gañán‐Gómez, I., Fulciniti, M. T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.011 · Cited by 160 · see citing works

GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity

Vartanian, A., Singh, S. K., Agnihotri, S., Jalali, S., Burrell, K. E., Aldape, K., & Zadeh, G. M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou035 · Cited by 153 · see citing works

Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest

Capello, M., Borgogno, S. F., Riganti, C., Chattaragada, M. S., Principe, M., Roux, C., Zhou, W., Petricoin, E. F., Cappello, P., & Novelli, F. (2015) · Oncotarget · doi:10.18632/oncotarget.6798 · Cited by 152 · see citing works

Aurora A ligand complex

Antonysamy, S., Pustilnik, A., Manglicmot, D., Froning, K., Weichert, K., & Wasserman, S. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6c2r/pdb · Cited by 148 · see citing works

Alpha-enolase regulates the malignant phenotype of pulmonary artery smooth muscle cells via the AMPK-Akt pathway

Dai, J., Zhou, Q., Chen, J., Rexius‐Hall, M. L., Rehman, J., & Zhou, G. (2018) · Nature Communications · doi:10.1038/s41467-018-06376-x · Cited by 149 · see citing works

Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance

Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 146 · see citing works

Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy

Wolpaw, A. J., & Dang, C. V. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.006 · Cited by 147 · see citing works

The Conundrum of Genetic “Drivers” in Benign Conditions

Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 147 · see citing works

Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies

Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144 · see citing works

Collateral lethality: a new therapeutic strategy in oncology

Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132 · see citing works

ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis

Lu, Y., Ju, H., Liu, Z., Chen, D.-L., Wang, Y., Zhao, Q., Wu, Q.-N., Zeng, Z.-L., Qiu, H.-B., Hu, P.-S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3155 · Cited by 141 · see citing works

Enolase 1, a Moonlighting Protein, as a Potential Target for Cancer Treatment

Qiao, G., Wu, A., Chen, X., Tian, Y., & Lin, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.63556 · Cited by 139 · see citing works

Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors

Morandi, A., Taddei, M. L., Chiarugi, P., & Giannoni, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00040 · Cited by 139 · see citing works

Riboregulation of Enolase 1 activity controls glycolysis and embryonic stem cell differentiation

Huppertz, I., Perez-Perri, J. I., Mantas, P., Sekaran, T., Schwarzl, T., Russo, F., Ferring–Appel, D., Koskova, Z., Dimitrova-Paternoga, L., Kafkia, E., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.05.019 · Cited by 138 · see citing works

Comprehensive Analysis of Glycolytic Enzymes as Therapeutic Targets in the Treatment of Glioblastoma

Sanzey, M., Rahim, S. A. A., Oudin, A., Dirkse, A., Kaoma, T., Vallar, L., Herold‐Mende, C. C., Bjerkvig, R., Golebiewska, A., & Niclou, S. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123544 · Cited by 130 · see citing works

Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer

Zheng, Y., Wu, C., Yang, J., Zhao, Y., Jia, H., Xue, M., Xu, D., Yang, F., Fu, D., Wang, C., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0146-6 · Cited by 122 · see citing works

The Damaging Effect of Passenger Mutations on Cancer Progression

McFarland, C. D., Yaglom, J. A., Wojtkowiak, J. W., Scott, J. G., Morse, D. L., Sherman, M. Y., & Mirny, L. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3283-t · Cited by 120 · see citing works

Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia

Niu, Y., Lin, Z., Wan, A., Sun, L., Yan, S., Liang, H., Zhan, S., Chen, D., Bu, X., Liu, P., et al. (2021) · Hepatology · doi:10.1002/hep.31846 · Cited by 115 · see citing works

Combination therapeutics in complex diseases

He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112 · see citing works

Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity

Lin, K., Xie, A., Rutter, J. C., Ahn, Y.-R., Lloyd-Cowden, J. M., Nichols, A., Soderquist, R. S., Koves, T. R., Muoio, D. M., MacIver, N. J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.011 · Cited by 102 · see citing works

Targeting tumor suppressor genes for cancer therapy

Liu, Y., Hu, X., Han, C., Wang, L., Zhang, X., He, X., & Lu, X. (2015) · BioEssays · doi:10.1002/bies.201500093 · Cited by 106 · see citing works

The origin of aging: imperfectness-driven non-random damage defines the aging process and control of lifespan

Gladyshev, V. N. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.05.004 · Cited by 109 · see citing works

Nuclear BK channels regulate gene expression via the control of nuclear calcium signaling

Li, B., Jie, W., Huang, L., Wei, P., Li, S., Luo, Z.-Y., Friedman, A. K., Meredith, A. L., Han, M., Zhu, X., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3744 · Cited by 107 · see citing works

Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations

Ajore, R., Raiser, D. M., McConkey, M. E., Jöud, M., Boidol, B., Mar, B. G., Saksena, G., Weinstock, D. M., Armstrong, S. A., Ellis, S. R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606660 · Cited by 106 · see citing works

Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities

Nichols, C. A., Gibson, W. J., Brown, M. S., Kosmicki, J. A., Busanovich, J. P., Wei, H. Y., Urbanski, L. M., Currimjee, N., Berger, A. C., Gao, G. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16399-y · Cited by 103 · see citing works

Transcriptome analysis of copper homeostasis genes reveals coordinated upregulation of SLC 31A1, SCO 1, and COX 11 in colorectal cancer

Barresi, V., Salinaro, A. T., Spampinato, G., Musso, N., Castorina, S., Rizzarelli, E., & Condorelli, D. F. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12060 · Cited by 105 · see citing works

Cancer genome-sequencing study design

Mwenifumbo, J. C., & Marra, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3445 · Cited by 102 · see citing works

Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases

Verstraete, K., & Savvides, S. N. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3371 · Cited by 97 · see citing works

SF2312 is a natural phosphonate inhibitor of enolase

Leonard, P. G., Satani, N., Maxwell, D., Lin, Y.-H., Hammoudi, N., Peng, Z., Pisaneschi, F., Link, T. M., Lee, G. R., Sun, D., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2195 · Cited by 96 · see citing works

Combinatorial CRISPR-Cas9 Metabolic Screens Reveal Critical Redox Control Points Dependent on the KEAP1-NRF2 Regulatory Axis

Zhao, D., Badur, M. G., Luebeck, J., Magaña, J. H., Birmingham, A., Šášik, R., Ahn, C. S., Ideker, T. E., Metallo, C. M., & Mali, P. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.01.017 · Cited by 95 · see citing works

Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology

Guo, S.-W. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz047 · Cited by 96 · see citing works

Down-regulation of the Antisense Mitochondrial Non-coding RNAs (ncRNAs) Is a Unique Vulnerability of Cancer Cells and a Potential Target for Cancer Therapy

Vidaurre, S., Fitzpatrick, C. J., Burzio, V. A., Briones, M., Villota, C., Villegas, J., Echenique, J., Oliveira-Cruz, L., Araya, M., Borgna, V., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558841 · Cited by 93 · see citing works

Paralog buffering contributes to the variable essentiality of genes in cancer cell lines

De Kegel, B., & Ryan, C. J. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008466 · Cited by 92 · see citing works

An enolase inhibitor for the targeted treatment of ENO1-deleted cancers

Lin, Y.-H., Satani, N., Hammoudi, N., Yan, V. C., Barekatain, Y., Khadka, S., Ackroyd, J. J., Georgiou, D. K., Pham, C.-D., Arthur, K., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00313-3 · Cited by 92 · see citing works

An update on therapeutic opportunities offered by cancer glycolytic metabolism

Granchi, C., Fancelli, D., & Minutolo, F. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.09.041 · Cited by 91 · see citing works

Alpha-Enolase i ENO1 i a potential target in novel immunotherapies

Novelli, F. (2016) · Frontiers in bioscience · doi:10.2741/4526 · Cited by 90 · see citing works

The regulatory roles and clinical significance of glycolysis in tumor

Qiao, Q., Hu, S., & Wang, X. (2024) · 癌症：英文版 · doi:10.1002/cac2.12549 · Cited by 87 · see citing works

Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model

Lineweaver, C. H., Davies, P. C. W., & Vincent, M. D. (2014) · BioEssays · doi:10.1002/bies.201400070 · Cited by 87 · see citing works

Translating insights into tumor evolution to clinical practice: promises and challenges

Fittall, M. W., & Loo, P. V. (2019) · Genome Medicine · doi:10.1186/s13073-019-0632-z · Cited by 88 · see citing works

Immune evasion in HPV − head and neck precancer–cancer transition is driven by an aneuploid switch involving chromosome 9p loss

William, W. N., Zhao, X., Bianchi, J. J., Lin, H. Y., Cheng, P., Lee, J. J., Carter, H. K., Alexandrov, L. B., Abraham, J. P., Spetzler, D. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022655118 · Cited by 82 · see citing works

Syrosingopine sensitizes cancer cells to killing by metformin

Benjamin, D., Colombi, M., Hindupur, S. K., Betz, C., Lane, H. A., El‐Shemerly, M., Lu, M., Quagliata, L., Terracciano, L., Moes, S., et al. (2016) · Science Advances · doi:10.1126/sciadv.1601756 · Cited by 85 · see citing works

Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures

Graham, N. A., Minasyan, A., Lomova, A., Cass, A. A., Balanis, N. G., Friedman, M., Chan, S. T., Zhao, S. R., Delgado, A., Go, J. L., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167159 · Cited by 75 · see citing works

DNA Mutations May Not Be the Cause of Cancer

Adjiri, A. (2017) · Oncology and Therapy · doi:10.1007/s40487-017-0047-1 · Cited by 75 · see citing works

Metabolic heterogeneity and adaptability in brain tumors

Badr, C. E., Silver, D. J., Siebzehnrübl, F. A., & Deleyrolle, L. P. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03569-w · Cited by 71 · see citing works

Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer

Luengo, A., Abbott, K. L., Davidson, S. M., Hosios, A. M., Faubert, B., Chan, S. H., Freinkman, E., Zacharias, L. G., Mathews, T. P., Clish, C. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13419-4 · Cited by 73 · see citing works

Oncogenic and Tumor-Suppressive Functions of NOTCH Signaling in Glioma

Parmigiani, E., Taylor, V., & Giachino, C. (2020) · Cells · doi:10.3390/cells9102304 · Cited by 71 · see citing works

Focal chromosomal copy number aberrations in cancer—Needles in a genome haystack

Krijgsman, O., Carvalho, B. G., Meijer, G. A., Steenbergen, R. D. M., & Ylstra, B. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.08.001 · Cited by 69 · see citing works

Targeting RB1 Loss in Cancers

Linn, P., Kohno, S., Sheng, J., Kulathunga, N., Yu, H., Zhang, Z., Voon, D. C., Watanabe, Y., & Takahashi, C. (2021) · Cancers · doi:10.3390/cancers13153737 · Cited by 69 · see citing works

Biological Relevance and Therapeutic Potential of the Hypusine Modification System

Pällmann, N., Braig, M., Sievert, H., Preukschas, M., Hermans‐Borgmeyer, I., Schweizer, M., Nagel, C., Neumann, M., Wild, P. J., Haralambieva, E., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664490 · Cited by 68 · see citing works

Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines

Kegel, B. D., Quinn, N., Thompson, N., Adams, D. J., & Ryan, C. J. (2021) · Cell Systems · doi:10.1016/j.cels.2021.08.006 · Cited by 65 · see citing works

The Contributions of HIF-Target Genes to Tumor Growth in RCC

Zhang, T., Niu, X., Liao, L., Cho, E.-A., & Yang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080544 · Cited by 67 · see citing works

Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH

Allen, E. L., Ulanet, D., Pirman, D. A., Mahoney, C. E., Coco, J., Si, Y., Chen, Y., Huang, L., Ren, J., Choe, S. E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.052 · Cited by 68 · see citing works

Determinants of nutrient limitation in cancer

Sullivan, M. R., & Heiden, M. G. V. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1611733 · Cited by 65 · see citing works

Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-κB Gene Network

Fang, J., Barker, B., Bolanos, L. C., Liu, X., Jerez, A., Makishima, H., Christie, S., Chen, X., Rao, D. S., Grimes, H. L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.062 · Cited by 66 · see citing works

CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer

Deng, T., Shen, P., Li, A., Zhang, Z., Yang, H., Deng, X., Peng, X., Hu, Z., Tang, Z., Liu, J., et al. (2021) · Theranostics · doi:10.7150/thno.54961 · Cited by 65 · see citing works

Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects

Gonçalves, E., Behan, F. M., Louzada, S., Arnol, D., Stronach, E. A., Yang, F., Yusa, K., Stegle, O., Iorio, F., & Garnett, M. J. (2019) · Genome biology · doi:10.1186/s13059-019-1637-z · Cited by 60 · see citing works

Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

Gougis, P., Bachelard, C. M., Kamal, M., Gan, H., Borcoman, E., Torossian, N., Bièche, I., & le Tourneau, C. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz055 · Cited by 47 · see citing works

Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q

Neggers, J. E., Paolella, B. R., Asfaw, A., Rothberg, M. V., Skipper, T. A., Yang, A., Kalekar, R. L., Krill-Burger, J. M., Dharia, N. V., Kugener, G., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108493 · Cited by 64 · see citing works

An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma

Wen, C., Huang, K., Jiang, L.-L., Lu, X., Dai, Y., Shi, M.-M., Tang, X.-M., Wang, Q., Zhang, X., Wang, P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914557116 · Cited by 61 · see citing works

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors

Henssen, A. G., Reed, C., Jiang, E., García, H. D., von Stebut, J., MacArthur, I. C., Hundsdoerfer, P., Kim, J. H., de Stanchina, E., Kuwahara, Y., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam9078 · Cited by 59 · see citing works

Glioblastoma Metabolism: Insights and Therapeutic Strategies

Bernhard, C., Reita, D., Martin, S., Entz‐Werlé, N., & Dontenwill, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119137 · Cited by 61 · see citing works

Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis

Guo, S. (2018) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12221 · Cited by 58 · see citing works

Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine

Barekatain, Y., Ackroyd, J. J., Yan, V. C., Khadka, S., Wang, L., Chen, K., Poral, A. H., Tran, T. T., Georgiou, D. K., Arthur, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24240-3 · Cited by 61 · see citing works

Targeting synthetic lethal paralogs in cancer

Ryan, C. J., Mehta, I., Kebabci, N., & Adams, D. J. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.002 · Cited by 59 · see citing works

Exploiting collateral damage

Lehner, B., & Park, S. (2012) · Nature · doi:10.1038/488284a · Cited by 5 · see citing works

Abstract 3837: Passenger deletion of ENO1 as a collateral lethality target in cancer

Lin, Y.-H., Satani, N., Hammoudi, N., Marszalek, J. R., Sun, Y., Protopopova, M. N., Francesco, M. E. D., Czakó, B., Wang, A., DePinho, R. A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-3837

Abstract 2831: Collateral lethality: A new target for personalized oncology

Lin, Y.-H., Hammoudi, N., Satani, N., Ackroyd, J. J., Khadka, S., Georgiou, D. K., Marszalek, J. R., Sun, Y., Protopopova, M. N., Francesco, M. E. D., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2831

An enolase inhibitor for the targeted treatment of ENO1-deleted cancers

Lin, Y.-H., Satani, N., Hammoudi, N., Yan, V. C., Barekatain, Y., Khadka, S., Ackroyd, J. J., Georgiou, D. K., Pham, C.-D., Arthur, K., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00313-3 · Cited by 92 · see citing works

Passenger deletions create cancer-specific Achilles heel

Flemming, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3826 · Cited by 1 · see citing works